Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
6-K
Dilutive issuance
confidence 95%
filed 2026-09-02
EX-99.1
The Company entered into a subscription agreement for a private placement of 701,272 Class A ordinary shares at $1.42598 per share for $1,000,000 aggregate proceeds. The shares are unregistered, issued in reliance on Section 4(a)(2) of the Securities Act and Rule 506(b) of Regulation D. This is a classic dilutive private placement (PIPE) by a CEO-led entity, constituting a related-party transaction requiring Audit Committee and Board approval under Nasdaq Listing Rule 5630.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-09-02
EX-99.1
This is a press release announcing Maris-Tech's financial results for the six months ended June 30, 2026, disclosing revenues of $2,077,545 (a 194% increase year-over-year), net loss of $2,816,584, and cash position of $2,387,801. The exhibit explicitly states "Maris-Tech Announces Financial Results for the Six Months Ended June 30, 2026" and references the Form 6-K furnished to the SEC on September 1, 2026. This is a material interim earnings disclosure that would affect a reasonable investor's assessment of the company's financial performance and trajectory.
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-02
EX-99.1
This press release announces a strategic deployment agreement with one of Israel's three largest defense companies for QTREX's AME technology, including exclusivity provisions and a phased commercial pathway with aggregate revenue potential in the tens of millions of dollars. While the partner's identity is confidential, the disclosure describes a material operational and commercial milestone—immediate system deployment, recurring consumables revenue, and structured procurement phases—that represents a significant business development for the company's core AME platform in the defense/aerospace sector. This is a material operational/strategic event rather than a discrete financial event (no debt, equity issuance, or M&A transaction is disclosed), and it does not fit the specific categories of ma_activity (no acquisition or merger), earnings_release (no financial results), or other named types.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-02
Item 1.01
This Item 1.01 discloses entry into the Fifth Amendment to a Business Combination Agreement dated September 2, 2026, extending the Outside Date to November 30, 2026. The underlying transaction involves Blue Acquisition Corp. merging with Blockfusion Digital Infrastructure, Inc., with Blue and Blockfusion becoming wholly-owned subsidiaries of Pubco, which will become a publicly traded company. This is a material acquisition/change of control transaction, and the amendment extends the deadline for consummation of the business combination.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-09-02
EX-99.1
This announcement discloses the completion of a domestic unsecured convertible corporate bond issuance by United Microelectronics Corporation, with total proceeds of NT$4,792,798,780 fully received and remitted to the depository bank. This constitutes creation of a new direct financial obligation (debt issuance) and is material to investors as it affects the company's capital structure and financial position.
View raw filing on EDGAR →
6-K
Earnings release
confidence 95%
filed 2026-09-02
EX-99.1
This exhibit is a press release announcing Yatsen's unaudited financial results for the second quarter ended June 30, 2026. It discloses key financial metrics including total net revenues (RMB1.14 billion, up 5.1% YoY), gross margin (73.9%, down from 78.3%), and net loss (RMB90.8 million vs. RMB19.5 million loss in prior year). The document explicitly states "Yatsen Announces Second Quarter 2026 Financial Results" and includes detailed segment performance, operating expense breakdowns, and forward guidance for Q3 2026. This is a discrete earnings announcement, not a periodic financial report filing.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-09-02
Item 1.01
Vertiv Holdings Co entered into an agreement and plan of merger to acquire Utility Innovation Holdings, Inc. for approximately $1.45 billion in upfront cash plus up to $1.15 billion in contingent earnout consideration based on EBITDA targets, with closing expected in Q4 2026 subject to regulatory approvals. The acquisition expands Vertiv's addressable market in power-constrained data centers by adding microgrid controls and behind-the-meter power architecture capabilities.
View raw filing on EDGAR →
8-K
Workforce Reduction
confidence 95%
filed 2026-09-02
Item 2.05
TScan announced a strategic reorganization involving a workforce reduction of approximately 75%, elimination of the internal manufacturing organization, and expected cumulative cost savings of $55.0 million through end of 2027, with employee-related costs of $4.1 million. The company is pausing enrollment in its Phase 3 ALLOHA-2 study and refocusing on in vivo solid tumor development to extend runway to Q4 2027.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-02
Item 3.01
TScan received written notice from Nasdaq on August 27, 2026, that its common stock failed to comply with the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), with an initial 180-day compliance period until February 23, 2027.
View raw filing on EDGAR →
8-K
Exec departure
confidence 75%
filed 2026-09-02
Item 5.02
TScan terminated the employment of Jason A. Amello (Chief Financial Officer) and Chrystal Louis, M.D., MPH (Chief Medical Officer), effective September 2, 2026, in connection with the strategic reorganization, with contractual severance entitlements.
View raw filing on EDGAR →
8-K
M&A activity
confidence 97%
filed 2026-09-02
Item 2.03
ScanSource completed its acquisition of MicroAge for $220.5 million in an all-cash transaction on September 1, 2026, funded through borrowings under its revolving credit facility. This material acquisition represents a significant capital deployment and strategic transaction affecting the registrant's financial position and growth strategy.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 95%
filed 2026-09-02
Item 8.01
The filing discloses CalciMedica's status regarding Nasdaq listing compliance. While the Company resolved one deficiency (market value of listed securities below $35 million minimum), it remains non-compliant with the Minimum Bid Price Requirement (stock below $1.00 per share) with a September 14, 2026 deadline to regain compliance. The disclosure explicitly states "There can be no assurance that the Company will be able to regain compliance with the Minimum Bid Price Requirement or otherwise maintain compliance with the other listing requirements," indicating material delisting risk.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
The filing discloses the appointment of Clay Ritchey as Chief Executive Officer and Board member, effective September 8, 2026. While the section also mentions Kevin Coop's departure as CEO, the principal disclosed action centers on the new CEO appointment with detailed employment terms including $500,000 base salary, 87.5% target bonus, and $4,000,000 in new hire equity awards. This is a material executive leadership change affecting investor assessment of company direction and governance.
View raw filing on EDGAR →
8-K
Exec departure
confidence 98%
filed 2026-09-02
Item 5.02
Geoffrey Parker, the Executive Vice President and Chief Financial Officer (principal financial officer), provided notice of retirement effective November 6, 2026. The departure of a CFO is a material executive change that would affect investor assessment of the company's financial leadership and continuity. This is a clear exec_departure event under Item 5.02(b).
View raw filing on EDGAR →
6-K
Operational Other
confidence 85%
filed 2026-09-02
EX-99.1
This media release discloses an unplanned outage at Algoma's Lake Superior Power generating facility that has disrupted steelmaking operations. While the company has resumed EAF production under interim arrangements since August 29, 2026, the disclosure addresses a material operational disruption and ongoing efforts to restore full generating capacity through turbine repair or replacement. This is a significant operational event affecting production and shipments, but does not fit the specific categories of workforce reduction, material litigation, debt covenant breach, or other named event types—making it an operational_other event.
View raw filing on EDGAR →
6-K
Earnings release
confidence 92%
filed 2026-09-02
EX-99.2
This exhibit is an announcement that Trip.com Group Limited will report its second quarter and first half 2026 financial results on September 15, 2026. Although it is technically a pre-announcement notice rather than the results themselves, it discloses the timing and logistics for the earnings announcement, which is a material event that investors rely upon to plan for earnings disclosure. The exhibit explicitly states the company "will announce its financial results for the three months and six months ended June 30, 2026," making this a disclosure of an imminent earnings release event.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-02
Item 7.01
The disclosure reports initial gold assay results from the 2026 surface diamond drilling program at the Lucky Shot Project and underground exploration development progress, including discovery of two previously unmodeled KM-style mineralized vein structures. This is a material operational/exploration milestone for an exploration-stage gold company, disclosing significant drill intercepts (2.45 meters grading 86.05 g/t Au) and new mineralized structures that advance the company's geologic model and exploration strategy, but does not constitute earnings, M&A activity, or other specifically-named event types.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-02
Item 8.01
The filing discloses the declaration of August 2026 dividends for John Hancock Comvest Private Income Fund's common shares, with Class I shares receiving $0.1871 per share (8.96% annualized yield), payable on or about September 24, 2026. This is a routine but material dividend distribution disclosure typical of closed-end funds, affecting shareholders' returns and reinvestment decisions.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-02
Item 8.01
The filing discloses receipt of a non-binding acquisition proposal from Advent International to acquire all outstanding Class A common stock and Definitive OpCo Units not already owned by Advent and Jason Krantz for $1.02 per share in an all-cash transaction. This constitutes a material M&A activity—specifically entry into preliminary acquisition discussions—that would materially affect a reasonable investor's assessment of the company's future. The formation of a Special Committee and engagement of financial and legal advisors underscore the materiality of this potential change-of-control transaction.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 75%
filed 2026-09-02
EX-99
HDFC Bank is exercising a call option to redeem INR 7,39,00,00,000 (approximately $88.7 million USD) in Additional Tier 1 Notes on September 30, 2026. While this is technically a redemption/retirement of existing debt rather than issuance of new debt, it represents a material capital event involving the modification or termination of a direct financial obligation. The redemption at par plus accrued interest is a significant debt transaction that affects the bank's capital structure and liquidity position, warranting disclosure to investors as a material financial event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-02
Item 3.02
The filing discloses an unregistered sale of 587,724.144 common shares of beneficial interest for approximately $11.8 million under Section 4(a)(2) and Regulation D. This is a classic private placement of equity securities exempt from registration, which is material to investors as it represents dilution and capital raising activity. The Item 3.02 designation and the specific exemption language confirm this is a dilutive issuance.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-02
Item 8.01
Ultragenyx disclosed failure of the Phase 3 Aspire study for apazunersen (GTX-102) to meet its primary and key secondary endpoints in Angelman syndrome treatment. The company announced it will evaluate the program's disposition and implement significant expense reductions. This is a material operational/clinical event affecting the company's pipeline and future operations, but does not fit the specific categories of earnings release, material impairment, or workforce reduction—it is a clinical development setback with strategic implications.
View raw filing on EDGAR →
8-K
Exec departure
confidence 95%
filed 2026-09-02
Item 5.02
Dr. Fawzi Benzaghou, the Company's Chief Medical Officer, is departing effective September 30, 2026, pursuant to a mutual agreement. While the disclosure mentions severance benefits, the principal disclosed action is the departure of a named executive officer from a key leadership position (CMO), making this an exec_departure event. The departure of a CMO at a biopharmaceutical company is material to investors assessing the company's medical and clinical capabilities.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-09-02
Item 2.02
This is a clear earnings release for Q2 2026 filed under Item 2.02 (Results of Operations and Financial Condition). The press release discloses quarterly financial results including collaboration revenue ($1.9M), R&D expenses ($8.8M), G&A expenses ($2.5M), and net loss ($6.5M), along with balance sheet items and cash position. The filing is material as it provides investors with the company's financial performance and runway guidance (funding into H1 2029).
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-02
Item 2.02
Netskope disclosed Q2 fiscal 2027 financial results (ended July 31, 2026) showing revenue of $220.5 million (up 29% YoY), ARR of $899 million (up 27% YoY), along with operating results, net loss per share, cash flow metrics, and forward guidance for Q3 and full-year fiscal 2027.
View raw filing on EDGAR →
8-K
Earnings release
confidence 97%
filed 2026-09-02
Item 2.02
Petco disclosed Q2 2026 financial results for the quarter ended August 1, 2026, reporting net sales of $1.5 billion, net income of $38.7 million, Adjusted EBITDA of $122.2 million, and comparable sales growth of 0.6%, with full-year outlook reaffirmation.
View raw filing on EDGAR →
8-K
M&A activity
confidence 95%
filed 2026-09-02
Item 2.01
FiscalNote completed the sale of its FrontierView subsidiary (Frontier Strategy Group, LLC) to Oxford Economics USA, Inc. for approximately $9.4 million in total consideration ($6.4 million cash at closing plus up to $3.0 million earnout), with the transaction closing on August 27, 2026. Proceeds were used to prepay $4.95 million of term loans, and the company updated full-year 2026 guidance to reflect the removal of FrontierView from results.
View raw filing on EDGAR →
8-K
Operational Other
confidence 75%
filed 2026-09-02
Item 1.01
Cogent Biosciences entered into a Commercial Supply Agreement with Hovione on September 1, 2026, to manufacture bezuclastinib spray-dried dispersion and bezuclastinib tablets. This is a material supply/manufacturing contract for the Company's product, with a five-year initial term and automatic renewals. While Item 1.01 typically covers M&A activity, this is a supply agreement rather than an acquisition, disposition, or change of control; it is a material operational/commercial contract that does not fit the specific M&A definition but is clearly material to the Company's business operations and product supply chain.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-09-02
Item 2.02
This is a clear earnings release disclosing Q2 2026 financial results for Attovia Therapeutics. The filing explicitly states "On September 2, 2026, Attovia Therapeutics, Inc. (the "Company") issued a press release reporting its financial results for the second quarter ended June 30, 2026" and furnishes the full press release as Exhibit 99.1. The exhibit includes condensed consolidated balance sheets and statements of operations showing revenue of $0.45 million, R&D expenses of $18.9 million, and net loss of $20.7 million for Q2 2026, along with corporate updates on clinical pipeline progress and the recently completed IPO.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-09-02
Item 5.02
The Board appointed James E. Olsson as Executive Vice President, Chief Growth Officer effective September 6, 2026, with oversight of direct businesses, retail stores, merchandising, planning, global sourcing, and brand strategy. His compensation package includes a base salary of $475,000, an RSU grant of $250,000, an annual bonus target of 60%, and LTIP participation.
View raw filing on EDGAR →
8-K
Delisting risk
confidence 98%
filed 2026-09-02
Item 3.01
IRIDEX received a formal Notice of Non-Compliance from Nasdaq on August 27, 2026, for failing to maintain the $1.00 minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The company has 180 calendar days (until February 23, 2027) to regain compliance, with potential delisting if it fails to do so. This is a textbook delisting-risk disclosure under Item 3.01, materially affecting investor assessment of the company's continued market access and trading status.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 85%
filed 2026-09-02
Item 1.01
West Bay BDC entered into a second amendment to its revolving credit facility that increases the Maximum Commitment amount to $460,000,000 and the Applicable Advance Rate to 80%, materially expanding the company's borrowing capacity and access to capital.
View raw filing on EDGAR →
8-K
Operational Other
confidence 85%
filed 2026-09-02
Item 7.01
Microsoft disclosed a material reorganization of its reportable segments and investor metrics effective FY27, transitioning from three segments (Productivity and Business Processes, Intelligent Cloud, More Personal Computing) to two segments (Agents and Infra, Devices and Consumer). This restructuring reflects how the company now manages operations and allocates resources in response to AI's impact on the business, and includes comprehensive restatement of historical financial data under the new structure. While this is a significant operational and strategic realignment affecting how investors will assess the company's performance going forward, it does not fit the specific categories of M&A activity, impairment, debt issuance, or other named event types—it is a structural business reorganization disclosed under Regulation FD.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-02
Item 3.02
The filing discloses an unregistered sale of equity securities (Class I and Class S common shares) totaling approximately $11.6 million in Class I shares and $100,000 in Class S shares, exempt under Section 4(a)(2) of the Securities Act and Regulation D/S. This is a classic dilutive issuance of unregistered equity to third-party investors, material to shareholders as it increases share count and dilutes existing ownership.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 95%
filed 2026-09-02
Item 8.01
Senior Credit Investments, LLC declared a distribution of $16.1572 per Unit to unitholders, payable in cash on September 18, 2026. This is a direct distribution of capital to security holders, which is the core definition of a dividend_distribution event. The material amount per unit and the formal declaration make this a material disclosure affecting investor returns.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-09-02
Item 8.01
The filing discloses a declared distribution to shareholders of Jefferies Credit Partners BDC Inc. for both Class I and Class S common shares, with specific per-share amounts ($0.1163 gross for Class I, $0.1163 gross for Class S with a $0.0103 servicing fee), payable on September 18, 2026. This is a routine but material dividend distribution typical of BDC filings, affecting shareholder returns and capital allocation.
View raw filing on EDGAR →
8-K
Auditor Change
confidence 98%
filed 2026-09-02
Item 4.01
This Item 4.01 discloses the dismissal of KPMG LLP as the independent registered public accounting firm effective September 2, 2026, and the concurrent appointment of Ernst & Young LLP as the successor auditor. The filing explicitly states there were no disagreements with KPMG on accounting principles, practices, or auditing scope, and no reportable events, indicating a routine auditor transition likely related to the Merger referenced in the text. Auditor changes are material governance events affecting investor confidence in financial reporting oversight.
View raw filing on EDGAR →
8-K
Dividend Distribution
confidence 98%
filed 2026-09-02
Item 8.01
The Board of Directors declared a quarterly cash dividend of $0.09 per share on common stock, payable October 7, 2026 to shareholders of record as of September 23, 2026. This is a straightforward dividend distribution disclosure, which is material to investors as it represents a return of capital and signals the company's capital allocation and financial health.
View raw filing on EDGAR →
8-K
Financial Other
confidence 75%
filed 2026-09-02
Item 1.02
The Company terminated a $250 million Equity Purchase Facility effective September 3, 2026, to pursue alternative financing options. The facility was never drawn upon, and the termination represents a strategic shift in the Company's financing strategy.
View raw filing on EDGAR →
8-K
Governance Other
confidence 75%
filed 2026-09-02
Item 7.01
The Company announced a special shareholder meeting scheduled for October 22, 2026, with a record date of September 4, 2026, concerning matters previously disclosed in a preliminary proxy statement filed August 7, 2026.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-02
Item 5.07
This Item 5.07 filing discloses the final voting results from Sunbelt's 2026 Annual Meeting of Stockholders held on September 1, 2026, covering four proposals: (i) election of ten directors, (ii) advisory approval of named executive officer compensation, (iii) advisory vote on say-on-pay frequency (approved as "1 Year"), and (iv) ratification of PricewaterhouseCoopers LLP as independent auditor. The detailed tabulation of FOR, AGAINST, ABSTAIN, and broker non-votes for each proposal is the core disclosure required by Item 5.07, making this a textbook shareholder vote results event.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-09-02
Item 1.01
DynaResource entered into Securities Purchase Agreements on September 1, 2026, issuing 6,666,666 units (comprising common stock and warrants) to multiple purchasers for $3,000,000 in aggregate proceeds under Section 4(a)(2) exemption. The private placement includes warrants exercisable at $0.51 per share, conditioned on stockholder approval to increase authorized shares, and involves voting agreements and waivers of preemptive rights.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-09-02
Item 5.07
LivePerson shareholders voted to approve the proposed merger with SoundHound AI at a special meeting held on September 2, 2026, with the Merger Proposal receiving 6,339,066 votes in favor, 134,018 against, and 19,874 abstentions. All conditions precedent to consummation have been satisfied and the parties expect to close on September 4, 2026, with merger consideration of 0.4673 shares of SoundHound Class A Common Stock plus $3.31 per share in cash.
View raw filing on EDGAR →
8-K
Debt Issuance
confidence 75%
filed 2026-09-02
Item 1.01
The filing discloses a third amendment to a senior secured revolving credit facility, with new lenders (Apple Bank and Sumitomo Mitsui Trust Bank) joining with combined commitments of $85.0 million. While the aggregate borrowing capacity remains at $200.0 million, the amendment represents a material modification to the registrant's direct financial obligations and credit arrangements. This is disclosed under Item 1.01 (Entry into a Material Definitive Agreement) and constitutes a material amendment to an existing credit facility.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-09-02
Item 5.02
Aric Chang was appointed as Chief Financial Officer of American Healthcare REIT, Inc., effective October 1, 2026, succeeding Brian S. Peay who is retiring after 10 years in the role. Chang brings extensive REIT finance and capital allocation experience from Public Storage, with compensation terms including a $500,000 base salary, 100% target bonus, $1,000,000 long-term incentive award, and $310,000 sign-on bonus.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-09-02
EX-99.1
This is an underwriting agreement for the issuance of 6.146% Subordinated Notes due 2041 by Manulife Financial Corporation. The document establishes the terms and conditions for the creation of a new direct financial obligation—subordinated debt securities—to be issued pursuant to a subordinated indenture. This is a material debt issuance event that would affect a reasonable investor's assessment of the company's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Earnings release
confidence 98%
filed 2026-09-02
Item 2.02
Gold.com issued a press release on September 2, 2026 disclosing financial results for fiscal Q4 and full year ended June 30, 2026, including revenues of $25.5 billion (132% increase YoY), net income of $82.3 million (375% increase), and diluted EPS of $3.02 (325% increase). The filing explicitly states "A copy of the Company's press release is attached hereto as Exhibit 99.1," which is the standard format for earnings releases under Item 2.02. The company also declared a special dividend of $1.00 per share, demonstrating material financial performance warranting investor disclosure.
View raw filing on EDGAR →
6-K
Debt Issuance
confidence 95%
filed 2026-09-02
EX-99.1
BW LPG successfully placed a USD 300 million offering of senior unsecured convertible bonds due 2031, creating a new direct financial obligation. The press release discloses key terms including the coupon rate (2.25% per annum), conversion price (USD 30.4870 per share), maturity date (9 September 2031), and intended use of proceeds for financing a newbuild program and general corporate purposes. This is a material capital-raising event that would affect a reasonable investor's assessment of the company's capital structure and financial obligations.
View raw filing on EDGAR →
6-K
M&A activity
confidence 95%
filed 2026-09-02
EX-99.1
Bitdeer announced the completed acquisition of approximately 200 acres of greenfield property in Milam County, Texas for approximately $100 million in cash. This is a material acquisition of a strategic real estate asset that directly supports the company's AI/HPC infrastructure development strategy and provides long-term operational control over a key facility location. The transaction is substantial in both financial terms and strategic importance to the company's growth plans.
View raw filing on EDGAR →
6-K
Operational Other
confidence 75%
filed 2026-09-02
EX-99.1
This press release announces a positive interim development in Can-Fite's pivotal Phase III trial of Namodenoson for hepatocellular carcinoma—specifically, longer-than-anticipated overall survival in the blinded study population and the company's decision to advance the timing of the planned interim analysis. While the company emphasizes that no treatment efficacy conclusions can yet be drawn (the study remains blinded), the announcement of improved survival metrics and acceleration of interim analysis represents a material operational/clinical milestone that would affect a reasonable investor's assessment of the drug candidate's development trajectory and commercial prospects. This is not a discrete earnings release, M&A event, or executive change, but rather a material clinical-development milestone.
View raw filing on EDGAR →